Evaluation of disease burden, patient journey, unmet diagnosis and treatment needs of patients with HIP and knee osteoarthritis in Turkey: A study through Delphi Methodology
- PMID: 36605849
- PMCID: PMC9807826
- DOI: 10.1016/j.ocarto.2022.100332
Evaluation of disease burden, patient journey, unmet diagnosis and treatment needs of patients with HIP and knee osteoarthritis in Turkey: A study through Delphi Methodology
Abstract
Objective: To get information-driven insights from expert physicians regarding multiple aspects of the patient journey in knee and hip OA and establish a consensus for future studies and decision tree models in Turkey.
Design: 157 questions were asked in total during this three-round modified Delphi-method panel to 10 physical medicine and rehabilitation specialists (2 have rheumatology and 3 have algology subspeciality), one orthopaedic surgeon and one algology specialist from anaesthesia specialty background. A consensus was achieved when 80% of the panel members agreed with an item. Contradictions between different disciplines were accepted as a non-consensus factor.
Results: Panellists agreed that American College of Rheumatology classification criteria is mostly sufficient to provide an OA diagnosis in clinical practice, OA patients with ≥5 Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain or physical function score can be defined as moderate-to-severe OA if they have an additional ≥2 Kellgren-Lawrence (KL) score, a minimum improvement of 30% from baseline in WOMAC pain or function subscales or in PGA score can be accepted as moderate treatment response where ≥50% improvement from baseline in those scores as substantial response. Panellists stated that arthroplasty procedures need to be delayed as long as possible, but this delay should not jeopardize a beneficial and successful operation.
Conclusions: These findings show that there is a significant disease burden, unmet treatment needs for patients with moderate-to-severe OA in Turkey from experts' perspective. Therefore, an updated systematic approach and decision tree models are needed to be implemented.
Keywords: arthroplasty; diagnosis; disease burden; osteoarthritis; severity; treatment response.
© 2022 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International (OARSI).
Conflict of interest statement
HFC received honorarium from MSD, Celltrion, Amgen. LA received honorarium from Pfizer, Abbvie, MSD, Exeltis, Sanovel, Lilly, Gensenta, Menarini, Nobel, Kocak. S. Ataman received honorarium from Abbvie, UCB and Novartis. SA, SH acted in advisory board of Pfizer. DD recevied honorarium from Santa Farma, Menarini, Exeltis, Sandoz and Expanscience. HG received honorarium from Pfizer and Menarini. AK recevied honorarium from Abbott, Abdi Ibrahim and Pfizer. MU received honorarium from Pfizer. BH is an employee and holding stock options of Pfizer. AO, SG and KH are employees of Pfizer.
References
-
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. 2020. http://ghdx.healthdata.org/gbd- results-tool (accessed November 2, 2020).
-
- Y1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. Osteoarthritis —level 3 cause. 2020. http://www.healthdata.org/results/gbd_summaries/2019/osteoarthritis- lev... (accessed November 2, 2020).
LinkOut - more resources
Full Text Sources
